A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study

Alzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug used to mitigate the disease progression, has low efficacy due to its limited permeability across the blood–brain barrier...

Full description

Bibliographic Details
Main Authors: Shafq Al-azzawi, Dhafir Masheta, Anna Guildford, Gary Phillips, Matteo Santin
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Nanomaterials
Subjects:
Online Access:https://www.mdpi.com/2079-4991/10/8/1590
id doaj-8e4ffc7241b24915a2961003a65d103f
record_format Article
spelling doaj-8e4ffc7241b24915a2961003a65d103f2020-11-25T03:20:49ZengMDPI AGNanomaterials2079-49912020-08-01101590159010.3390/nano10081590A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro StudyShafq Al-azzawi0Dhafir Masheta1Anna Guildford2Gary Phillips3Matteo Santin4Centre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKAlzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug used to mitigate the disease progression, has low efficacy due to its limited permeability across the blood–brain barrier (BBB). In a previous work, FP was coupled at the uppermost branching of an ε-lysine-based branched carrier, its root presenting a phenylalanine moiety able to increase the hydrophobicity of the complex and enhance the transport across the BBB by adsorptive-mediated transcytosis (AMT). The present study explores a different molecular design of the FP-peptide delivery system, whereby its root presents an ApoE-mimicking peptide, a targeting ligand that could enhance transport across the BBB by receptor-mediated transcytosis (RMT). The functionalised complex was synthesised using a solid-phase peptide synthesis and characterised by mass spectrometry and FTIR. Cytotoxicity and permeability of this complex across an in vitro BBB model were analysed. Moreover, its activity and degradation to release the drug were investigated. The results revealed successful synthesis and grafting of FP molecules at the uppermost molecular branches of the lysine terminal without observed cytotoxicity. When covalently linked to the nanocarrier, FP was still active on target cells, albeit with a reduced activity, and was released as a free drug upon hydrolysis in a lysosome-mimicking medium. Noticeably, this work shows the high efficiency of RMT-driven FP delivery over delivery systems relying on AMT.https://www.mdpi.com/2079-4991/10/8/1590Alzheimer’s diseaseneurodegenerative diseasesblood–brain barrierApoE-peptidedrug delivery systemflurbiprofen
collection DOAJ
language English
format Article
sources DOAJ
author Shafq Al-azzawi
Dhafir Masheta
Anna Guildford
Gary Phillips
Matteo Santin
spellingShingle Shafq Al-azzawi
Dhafir Masheta
Anna Guildford
Gary Phillips
Matteo Santin
A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
Nanomaterials
Alzheimer’s disease
neurodegenerative diseases
blood–brain barrier
ApoE-peptide
drug delivery system
flurbiprofen
author_facet Shafq Al-azzawi
Dhafir Masheta
Anna Guildford
Gary Phillips
Matteo Santin
author_sort Shafq Al-azzawi
title A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
title_short A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
title_full A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
title_fullStr A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
title_full_unstemmed A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
title_sort peptide-based nanocarrier for an enhanced delivery and targeting of flurbiprofen into the brain for the treatment of alzheimer’s disease: an in vitro study
publisher MDPI AG
series Nanomaterials
issn 2079-4991
publishDate 2020-08-01
description Alzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug used to mitigate the disease progression, has low efficacy due to its limited permeability across the blood–brain barrier (BBB). In a previous work, FP was coupled at the uppermost branching of an ε-lysine-based branched carrier, its root presenting a phenylalanine moiety able to increase the hydrophobicity of the complex and enhance the transport across the BBB by adsorptive-mediated transcytosis (AMT). The present study explores a different molecular design of the FP-peptide delivery system, whereby its root presents an ApoE-mimicking peptide, a targeting ligand that could enhance transport across the BBB by receptor-mediated transcytosis (RMT). The functionalised complex was synthesised using a solid-phase peptide synthesis and characterised by mass spectrometry and FTIR. Cytotoxicity and permeability of this complex across an in vitro BBB model were analysed. Moreover, its activity and degradation to release the drug were investigated. The results revealed successful synthesis and grafting of FP molecules at the uppermost molecular branches of the lysine terminal without observed cytotoxicity. When covalently linked to the nanocarrier, FP was still active on target cells, albeit with a reduced activity, and was released as a free drug upon hydrolysis in a lysosome-mimicking medium. Noticeably, this work shows the high efficiency of RMT-driven FP delivery over delivery systems relying on AMT.
topic Alzheimer’s disease
neurodegenerative diseases
blood–brain barrier
ApoE-peptide
drug delivery system
flurbiprofen
url https://www.mdpi.com/2079-4991/10/8/1590
work_keys_str_mv AT shafqalazzawi apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT dhafirmasheta apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT annaguildford apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT garyphillips apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT matteosantin apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT shafqalazzawi peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT dhafirmasheta peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT annaguildford peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT garyphillips peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
AT matteosantin peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy
_version_ 1724616475409383424